Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs Williams Companies Inc (WMB) Price & Performance

Citius Pharmaceuticals IncTrade
Williams Companies IncTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs Williams Companies Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.76 (market cap $20.01M), while Williams Companies Inc trades at $73.72 (market cap $88.45B). The key difference: Williams Companies Inc is far larger — about 4420.3× Citius Pharmaceuticals Inc's market cap, and Williams Companies Inc pays a 2.9% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CTXRWMB
Market Cap
$20.01M$88.45B
Sector
HealthEnergy
52-Week High
$1.82$79.40
52-Week Low
$0.48$56.51
Enterprise Value
$16.23M$119.07B
Dividend Yield
2.9%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.

The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.

Williams Companies Inc

WMB trades at $73.72, up 2.6% today, with a bullish technical signal and strong analyst support. The company reported mixed quarterly earnings but raised full-year EBITDA guidance to $8.4 billion following its $5.5 billion acquisition of Momentum Midstream, enhancing its Gulf Coast footprint. Fundamentals show robust profitability with a 25.18% net income margin and 24.02% ROE, though valuation multiples like a P/E of 28.81 appear elevated.

The outlook is positive, driven by growth initiatives and stable cash flows, but risks include execution of the large acquisition and sensitivity to energy demand. With a consensus price target of $87.14 implying 18% upside, the stock offers growth potential tempered by integration challenges and debt levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About Williams Companies Inc

Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.

Read more on WMB